BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGFnews2026-04-28T14:42:57+00:00April 28th, 2026|Endpoints News|
Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrelnews2026-04-28T13:20:17+00:00April 28th, 2026|Endpoints News|
Lilly strikes second partnership this year for recombinase-based gene editingnews2026-04-28T11:00:57+00:00April 28th, 2026|Endpoints News|
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitornews2026-04-27T12:36:19+00:00April 27th, 2026|Endpoints News|
Sun Pharma to buy Organon for $11.75B in major portfolio expansionnews2026-04-27T06:16:16+00:00April 27th, 2026|Endpoints News|
Rigel loses Lilly alliance in pharma industry’s latest RIPK exitnews2026-04-22T14:41:53+00:00April 22nd, 2026|Endpoints News|
Soleno sold at a discount to Neurocrine due to dwindling European prospectsnews2026-04-21T10:33:59+00:00April 21st, 2026|Endpoints News|
Kelonia investor Venrock will clear a 45-fold return on startup’s sale to Lillynews2026-04-20T14:49:30+00:00April 20th, 2026|Endpoints News|
Lilly to buy Kelonia for $3.25B upfront, underlining its in vivo CAR-T strategynews2026-04-20T13:25:03+00:00April 20th, 2026|Endpoints News|
UCB plots epilepsy expansion with $650M Neurona cell therapy acquisitionnews2026-04-20T01:45:33+00:00April 20th, 2026|Endpoints News|
